Results 1 to 10 of about 78 (68)
Tumor-associated Tn and STn antigens: from molecular mechanism to precision diagnosis and treatment
Frontiers in ImmunologyBackgroundAbnormal protein glycosylation is a key feature of tumors. Among the modifications, Tn antigen (GalNAcα1-Ser/Thr) and its sialylated derivative, STn antigen (Neu5Acα2-6GalNAcα1-O-Ser/Thr), are prominent tumor-associated carbohydrate antigens ...
Shuailong Zhao +7 more
doaj +6 more sources
Frontiers in Immunology, 2023 Targeted therapies are the state of the art in oncology today, and every year new Tumor-associated antigens (TAAs) are developed for preclinical research and clinical trials, but few of them really change the therapeutic scenario. Difficulties, either to
Iris Lodewijk +11 more
doaj +4 more sources
Improving the Antigenicity of sTn Antigen by Modification of Its Sialic Acid Residue for Development of Glycoconjugate Cancer Vaccines [PDF]
Bioconjugate Chemistry, 2006 Sialyl Tn (sTn) antigen is a sialylated disaccharide abundantly expressed by many tumors. To search for effective cancer immunotherapies based on sTn antigen, we designed and synthesized a series of unnatural N-acyl derivatives of sTn and studied their immunological properties.
Zhongwu Guo
exaly +3 more sources
Synthesis of a C-Glycoside Analogue of sTn: An HIV- and Tumor-Associated Antigen† [PDF]
Angewandte Chemie - International Edition, 2003 N-Acetylneuraminic acid occupies the nonreducing end of many naturally occurring glycoconjugates on the cell surface, including glycoproteins and glycolipids. The strategic location of glycoconjugates on the cell surface and the enormous structural information that they carry account for their major role in biological recognition in the control of both
Robert J. Linhardt
exaly +3 more sources
A Comprehensive Analysis of Tn and STn Antigen Expression in Esophageal Adenocarcinoma
CancersDifferential glycosylation, marked by the presence of truncated O-glycans, is a distinctive feature of epithelial-derived cancers. However, there is a notable gap in research regarding the expression of Tn and STn antigens in esophageal adenocarcinoma (EAC). To address this, we employed commercially available antibodies, previously validated for Tn and
Gerrit Wolters-Eisfeld +2 more
exaly +3 more sources
BMC Cancer, 2022 Background Routine measurement of tumor markers is not recommended in daily clinical practice for patients with cancer of unknown primary (CUP). We evaluated the diagnostic value of tumor markers in identifying favorable or unfavorable subsets in ...
Shigemasa Takamizawa +14 more
doaj +1 more source
Polymeric nanoparticles targeting Sialyl-Tn in gastric cancer: A live tracking under flow conditions
Materials Today Bio, 2022 Drug delivery using nanoparticles (NPs) represents a potential approach for therapy in cancer, such gastric cancer (GC) due to their targeting ability and controlled release properties.
Francisca Diniz +8 more
doaj +1 more source
Cancer Medicine, 2021 Background Mucin‐associated sialyl‐Tn (sTn) antigen is overexpressed and related with adverse outcome in breast cancer (BC). The role of sTn in BC has not been well defined in pathological nipple discharge (PND) cytology.
Feng Xu +5 more
doaj +1 more source
Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma. [PDF]
PLoS ONE, 2018 The expression of Sialyl-Tn (STn) in tumors is associated with metastatic disease, poor prognosis, and reduced overall survival. STn is expressed on ovarian cancer biomarkers including CA-125 (MUC16) and MUC1, and elevated serum levels of STn in ovarian ...
David A Eavarone +8 more
doaj +1 more source
BMC Cancer, 2022 Background The Tn antigen (CD175) is an O-glycan expressed in various types of human adenocarcinomas, including colorectal cancer (CRC), though prior studies have relied heavily upon poorly characterized in-house generated antibodies and lectins. In this
Gabrielle E. Dombek +11 more
doaj +1 more source